93 related articles for article (PubMed ID: 18988899)
21. Cooperation between p27 and p107 during endochondral ossification suggests a genetic pathway controlled by p27 and p130.
Yeh N; Miller JP; Gaur T; Capellini TD; Nikolich-Zugich J; de la Hoz C; Selleri L; Bromage TG; van Wijnen AJ; Stein GS; Lian JB; Vidal A; Koff A
Mol Cell Biol; 2007 Jul; 27(14):5161-71. PubMed ID: 17502351
[TBL] [Abstract][Full Text] [Related]
22. Deregulation of specific E2F complexes by the v-mos oncogene.
Afshari CA; Rhodes N; Paules RS; Mudryj M
Oncogene; 1997 Jun; 14(25):3029-38. PubMed ID: 9223666
[TBL] [Abstract][Full Text] [Related]
23. Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density.
Wang Z; Hu H; Li G; Lee HJ; Jiang C; Kim SH; Lü J
Int J Cancer; 2008 Jan; 122(1):15-24. PubMed ID: 17847021
[TBL] [Abstract][Full Text] [Related]
24. p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription.
Wang CH; Chang HC; Hung WC
J Cell Physiol; 2006 Jul; 208(1):246-52. PubMed ID: 16575904
[TBL] [Abstract][Full Text] [Related]
25. RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors.
Zhang S; Tang Q; Xu F; Xue Y; Zhen Z; Deng Y; Liu M; Chen J; Liu S; Qiu M; Liao Z; Li Z; Luo D; Shi F; Zheng Y; Bi F
Mol Cancer Res; 2009 Apr; 7(4):570-80. PubMed ID: 19372585
[TBL] [Abstract][Full Text] [Related]
26. The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.
O'Connor RJ; Schaley JE; Feeney G; Hearing P
Oncogene; 2001 Apr; 20(15):1882-91. PubMed ID: 11313936
[TBL] [Abstract][Full Text] [Related]
27. Genetic alterations in a telomerase-immortalized human esophageal epithelial cell line: implications for carcinogenesis.
Cheung PY; Deng W; Man C; Tse WW; Srivastava G; Law S; Tsao SW; Cheung AL
Cancer Lett; 2010 Jul; 293(1):41-51. PubMed ID: 20092939
[TBL] [Abstract][Full Text] [Related]
28. P300 plays a role in p16(INK4a) expression and cell cycle arrest.
Wang X; Pan L; Feng Y; Wang Y; Han Q; Han L; Han S; Guo J; Huang B; Lu J
Oncogene; 2008 Mar; 27(13):1894-904. PubMed ID: 17906698
[TBL] [Abstract][Full Text] [Related]
29. Myeloproliferative disorder by TKO.
Adams GB
Cell Stem Cell; 2008 Oct; 3(4):361-2. PubMed ID: 18940726
[TBL] [Abstract][Full Text] [Related]
30. Differential regulation of the cell cycle by alpha1-adrenergic receptor subtypes.
Gonzalez-Cabrera PJ; Shi T; Yun J; McCune DF; Rorabaugh BR; Perez DM
Endocrinology; 2004 Nov; 145(11):5157-67. PubMed ID: 15297446
[TBL] [Abstract][Full Text] [Related]
31. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling.
van Harn T; Foijer F; van Vugt M; Banerjee R; Yang F; Oostra A; Joenje H; te Riele H
Genes Dev; 2010 Jul; 24(13):1377-88. PubMed ID: 20551164
[TBL] [Abstract][Full Text] [Related]
32. The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G1-prolongation of NIH3T3 cells.
Chen Y; Knudsen ES; Wang JY
Oncogene; 1996 Oct; 13(8):1765-71. PubMed ID: 8895523
[TBL] [Abstract][Full Text] [Related]
33. Sphingosine-1-phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells.
Hsieh HL; Wu CB; Sun CC; Liao CH; Lau YT; Yang CM
J Cell Physiol; 2006 Jun; 207(3):757-66. PubMed ID: 16508949
[TBL] [Abstract][Full Text] [Related]
34. The role of p16 in the E2F-dependent thymidine kinase regulation.
Hengstschläger M; Hengstschläger-Ottnad E; Pusch O; Wawra E
Oncogene; 1996 Apr; 12(8):1635-43. PubMed ID: 8622883
[TBL] [Abstract][Full Text] [Related]
35. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop.
Howard CM; Claudio PP; De Luca A; Stiegler P; Jori FP; Safdar NM; Caputi M; Khalili K; Giordano A
Cancer Res; 2000 May; 60(10):2737-44. PubMed ID: 10825149
[TBL] [Abstract][Full Text] [Related]
36. E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes.
Parreño M; Garriga J; Limón A; Albrecht JH; Graña X
Oncogene; 2001 Aug; 20(35):4793-806. PubMed ID: 11521191
[TBL] [Abstract][Full Text] [Related]
37. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.
Alonso MM; Fueyo J; Shay JW; Aldape KD; Jiang H; Lee OH; Johnson DG; Xu J; Kondo Y; Kanzawa T; Kyo S; Bekele BN; Zhou X; Nigro J; McDonald JM; Yung WK; Gomez-Manzano C
J Natl Cancer Inst; 2005 Nov; 97(21):1589-600. PubMed ID: 16264179
[TBL] [Abstract][Full Text] [Related]
38. Effects of PPAR-α agonist and IGF-1 on estrogen sulfotransferase in human vascular endothelial and smooth muscle cells.
Li Y; Xu Y; Li X; Qin Y; Hu R
Mol Med Rep; 2013 Jul; 8(1):133-9. PubMed ID: 23685729
[TBL] [Abstract][Full Text] [Related]
39. Cytostatic and cytotoxic properties of chimeric peptides containing cyclin-inhibiting fragments.
Kulinich TM; Kharchenko VP; Filyasova EI; Shishkin AM; Bozhenko VK
Bull Exp Biol Med; 2008 Jan; 145(1):37-40. PubMed ID: 19023997
[TBL] [Abstract][Full Text] [Related]
40. For better or worse? Telomerase inhibition and cancer.
de Lange T; Jacks T
Cell; 1999 Aug; 98(3):273-5. PubMed ID: 10458601
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
